Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Abrocitinib in Healthy Chinese Participants
NCT04099563Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abrocitinib in atopic dermatitis (AD), sponsored by Pfizer. Primary endpoints: Area Under the Curve From Time Zero to Extrapolated Infinite Time, Maximum Observed Plasma Concentration and 2 more. Started Oct 2019; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04099563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04099563.